Stereotaxis, Inc. designs, manufactures and markets cardiology instrument control system for use in a hospital's interventional medical suite, or interventional lab, for the treatment of arrhythmias and coronary artery disease by enabling therapeutic solutions and improving catheter-based, or interventional, procedures. Its Niobe system allows physicians to navigate catheters, guidewires and other delivery devices through the blood vessels and chambers of the heart to treatment sites to effect treatment. The Company's Odyssey Enterprise Solution allows physicians to utilize a consolidated user interface and single mouse and keyboard control for multiple systems within the interventional lab. The Niobe system is designed for use by interventional electrophysiologists in the treatment of abnormal heart rhythms known as arrhythmias and by interventional cardiologists in the treatment of coronary artery disease.
 | Webcast
Q2 2011 Stereotaxis Inc Earnings Conference Call (Replay)
08/08/11 at 4:30 p.m. ET | | Webcast
Stereotaxis Inc at Stifel, Nicolaus & Company Inc. Healthcare Conference (Replay)
09/07/11 at 4:25 p.m. ET | Stereotaxis' proprietary magnetic systems and disposable devices allow physicians' to conduct precise, image-guided, computerized remote control interventional procedures designed to provide greater efficacy, efficiency, predictability, ease of use and safety for both routine and complex procedures in electrophysiology and interventional cardiology, including procedures in arrhythmia diagnosis and ablation, cardiac resynchronization therapy and complex occlusion recanalization. Physicians direct procedures from outside the x-ray field via a digital user interface with "point and click", "joystick" and "push button" controls. Stereotaxis has integrated its products with leading cath lab imaging technologies through alliances with industry leaders. The Company's core products have regulatory clearances and approvals in the U.S., Europe and Canada. |  | |
Dan Johnston Chief Financial Officer Stereotaxis, Inc. 